EUVIMEDEUVIMED entdecken
Crossref

Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling

Shixing Zhu iD, Ding Yu, Xunqiang Wang, Xin Wang iD

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.6111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Shixing Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medicine Department, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China. Hauptthemen laut MEDLINE: Drug Interactions, Itraconazole, Rifampin, Models, Biological. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel dual PI3K α/δ inhibitor, TQ‐B3525, has been developed for the targeted treatment of lymphoma and solid tumors. TQ‐B3525 is primarily metabolized by CYP3A4 and FOM3, while also serving as a substrate for the P‐glycoprotein transporter. The aim of this study was to anticipate the drug–drug interaction (DDI) of TQ‐B3525 and its two metabolites with CYP3A4 enzyme potent inducer (rifampicin) and CYP3A4/P‐gp inhibitor (itraconazole) utilizing a physiologically based pharmacokinetic (PBPK) modeling approach. Clinical data from healthy and cancer patient adults were employed to construct and evaluate the PBPK model for TQ‐B3525, M3, and M8‐3. Models involving rifampicin combined with midazolam, itraconazole combined with midazolam or digoxin were utilized to showcase the robustness of evaluating DDI effects. The simulated drug exposure of TQ‐B3525, M3, and M8‐3 in healthy and patient adults were consistent with clinical data, and the mean fold error values were within the acceptable ranges. The simulated results of positive substrates correspond to those reported in the literature. Co‐administration with rifampicin reduces C max and AUC of TQ‐B3525 to 76.1% and 46.0%, while increasing the levels of M3 and M8‐3. With itraconazole, C max and AUC of TQ‐B3525 rise to 131% and 204%, but decrease substantially for M3 and M8‐3. PBPK model simulation results showed that the systemic exposure of TQ‐B3525 was significantly affected when co‐administered with CYP3A4/P‐gp inducers and inhibitors. This indicates that the combination with strong inducers and inhibitors should be carefully avoided or adjust the dosage of TQ‐B3525 in clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsItraconazoleRifampinModels, BiologicalHumansAdultMalePhosphoinositide-3 Kinase InhibitorsCytochrome P-450 CYP3A InducersMidazolamFemaleCytochrome P-450 CYP3AClass I Phosphatidylinositol 3-KinasesMiddle AgedDigoxinCytochrome P-450 CYP3A InhibitorsNeoplasmsYoung Adult

Stichwörter der Autor:innen

DDIPBPKPI3Kα/δ inhibitorTQ‐B3525metabolites

Substanzen

ItraconazoleRifampinPhosphoinositide-3 Kinase InhibitorsCytochrome P-450 CYP3A InducersMidazolamCytochrome P-450 CYP3AClass I Phosphatidylinositol 3-KinasesPIK3CD protein, humanDigoxinCytochrome P-450 CYP3A Inhibitors

Autor:innen und Institutionen

  • Clinical Medicine Department, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.

ORCID-Profile: Shixing Zhu, Xin Wang

Zitieren

APA

Zhu, S., Yu, D., Wang, X., & Wang, X. (2024). Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.6111

Vancouver

Zhu S, Yu D, Wang X, Wang X. Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.6111

BibTeX
@article{Zhu2024,
  author = {Zhu, Shixing and Yu, Ding and Wang, Xunqiang and Wang, Xin},
  title = {Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.6111}
}
Kostenlos starten →